ADVERTISEMENT

Roche’s Actemra Helps Critically Ill Covid Patients in Test

Roche’s Actemra Helps Critically Ill Covid Patients in Test

Roche Holding AG’s rheumatoid arthritis medicine Actemra helps severely ill patients survive Covid-19, according to the early results of an international clinical trial.

Patients in intensive care were more likely to improve after taking the medicine, spending less time on organ-support machines, Imperial College London said in a statement Thursday.

The evidence comes from an interim analysis of a broad study that’s testing multiple treatments against Covid-19 as the reported number of deaths globally nears 1.4 million.

Treatment with Actemra has yielded conflicting results, but an observational study released last month also pointed to a survival benefit.

Imperial College’s interim analysis included data from the first 303 patients randomly assigned to receive immune-modulation treatments. Besides Actemra, they included Regeneron Pharmaceuticals Inc. and Sanofi’s Kevzara, Swedish Orphan Biovitrum AB’s Kineret and the immune substance interferon. The findings were not peer-reviewed.

©2020 Bloomberg L.P.